VST BIO公司宣布A轮融资以推进VB-001，并将威廉·塞萨加入董事会-动脉网

VST BIO Corporation Announces Series A Financing to Advance VB-001 and Adds William Sessa to Board of Directors

PR Newswire 等信源发布 2026-03-17 19:32



可切换为仅中文







SAN DIEGO

圣地亚哥

，

March 17, 2026

2026年3月17日

/PRNewswire/ -- VST BIO Corporation ('VST BIO'), a biotechnology company developing stroke therapeutics, announces the closing of its Series A financing, led by Coefficient Giving, a philanthropic funder and advisor that partners with donors on cost-effective, high-impact giving across issues such as global health, science R&D and more.

/PRNewswire/ -- VST BIO公司（“VST BIO”），一家致力于开发中风治疗药物的生物技术公司，宣布完成了由Coefficient Giving领投的A轮融资。Coefficient Giving是一家慈善资助者和顾问机构，与捐赠者合作，在全球健康、科学研发等领域进行高效益、低成本的捐赠。

Coefficient Giving funding partners have invested a total of $45MM since the company's inception in 2020. Proceeds from the Series A will enable the company to advance its lead program into first-in-human studies in 2026, expand its platform, and build core development capabilities..

自2020年公司成立以来，Coefficient的资助合作伙伴已累计投资4500万美元。A轮融资的收益将使该公司能够在其主导项目中推进到2026年进行首次人体研究，扩展其平台，并建立核心开发能力。

'We are pleased to have completed this financing to support advancement of VB-001 for the benefit of stroke patients,' said Krisztina Zsebo Ph.D., CEO and Chairman of the Board of VST BIO. Dr. Zsebo continued, 'The positive results of our monoclonal antibody in stroke preclinical studies demonstrated the potential of VB-001 to become an important treatment for patients with acute ischemic stroke.'.

“我们很高兴完成了这项融资，以支持VB-001的进展，造福中风患者，”VST BIO首席执行官兼董事会主席Krisztina Zsebo博士表示。Zsebo博士继续说道：“我们的单克隆抗体在中风临床前研究中的积极结果展示了VB-001成为急性缺血性中风患者重要治疗手段的潜力。”

As part of the financing, VST BIO has appointed William Sessa, to its Board of Directors, effective March 3, 2026. Bill most recently has served as SVP and CSO for Internal Medicine at Pfizer until mid-2025, where he was responsible for early-stage discovery to phase 2b programs. At Pfizer, he started innovative programs targeting the interface of metabolic driven, cardio-renal syndrome and advanced several NCEs into the clinic.

作为融资的一部分，VST BIO 已任命威廉·塞萨（William Sessa）为公司董事会成员，自2026年3月3日起生效。比尔（Bill）直至2025年中期一直担任辉瑞（Pfizer）内科高级副总裁兼首席科学官（SVP和CSO），负责从早期发现到2b阶段的项目。在辉瑞期间，他启动了针对代谢驱动、心肾综合征相关界面的创新项目，并将多个新化学实体（NCE）推进到临床阶段。

He is also Alfred Gilman Emeritus Professor in the Department of Pharmacology at Yale School of Medicine..

他还是耶鲁大学医学院药理学系的阿尔弗雷德·吉尔曼荣誉教授。

'Bill Sessa brings decades of experience in translating vascular therapeutics from basic research to proof-of-concept clinical trials, that will be invaluable as we enter our next phase of growth,' said Michael Simons, co-founder of VST BIO. 'His insights in drug development will strengthen our ability to deliver on our mission to stroke patients.'.

“比尔·塞萨在将血管治疗从基础研究转化为概念验证临床试验方面拥有数十年的经验，这将在我们进入下一个增长阶段时发挥不可估量的作用，”VST BIO联合创始人迈克尔·西蒙斯表示。“他在药物开发方面的见解将增强我们为中风患者实现使命的能力。”

'I am excited to work with VST BIO who is developing a first in class molecule targeting vascular inflammation in stroke patients. This bold approach, supported by extensive pre-clinical data, has the potential to transform the landscape for patients with this debilitating disease,' said Bill Sessa..

“我非常期待与VST BIO合作，他们正在开发一种针对中风患者血管炎症的首创新药分子。这一大胆的方法得到了广泛的临床前数据支持，有潜力改变这种衰弱性疾病患者的治疗前景，”Bill Sessa表示。

About VST BIO Corporation

关于VST生物公司

VST BIO is a preclinical-stage biotechnology company focused on vascular diseases, e.g., developing first-in-class antibodies targeting edema and inflammation for patients with ischemic stroke. The company's lead candidate, VB-001 has demonstrated efficacy in a number of diseases including stroke, sepsis, and has the potential to reduce cytokine release syndrome in a number of clinical settings.

VST BIO是一家处于临床前阶段的生物技术公司，专注于血管疾病，例如开发针对水肿和炎症的首创抗体，用于治疗缺血性中风患者。该公司主要候选药物VB-001已在多种疾病（包括中风、败血症）中显示出疗效，并有潜力在多种临床环境中减少细胞因子释放综合征。

VST BIO is headquartered in San Diego, CA..

VST BIO总部位于加利福尼亚州圣地亚哥。

For more information, please visit

有关更多信息，请访问

www.vst-bio.com

About Coefficient Giving

关于系数捐赠

Coefficient Giving is a philanthropic funder and advisor that works with donors who share its commitment to cost-effective, high-impact giving. Since 2014, it has directed more than $4 billion in grants across more than a dozen cause areas and has conducted in-depth research to identify the areas where philanthropic capital can have the greatest impact. .

系数捐赠是一家慈善资助者和顾问，与认同其成本效益高、高影响力捐赠理念的捐赠者合作。自2014年以来，它已在十几个重点领域指导了超过40亿美元的拨款，并进行了深入研究，以确定慈善资本能够产生最大影响的领域。

Coefficient Giving partners with major philanthropists to support their giving, providing research on cause areas and specific giving opportunities, strategic guidance on how to maximize impact, and operational support. For more information, visit

系数捐赠合作伙伴与主要慈善家合作支持他们的捐赠，提供关于事业领域和具体捐赠机会的研究、如何最大化影响力的策略指导以及运营支持。欲了解更多信息，请访问

coefficientgiving.org

系数提供.org

。

Media and Investor Contacts

媒体和投资者联系方式

Rebecque Laba, COO

雷贝克·拉巴，首席运营官

VST BIO Corporation

VST生物公司

(858) 665-2009

[email protected]